When was Immunome founded?

Immunome was founded in 2008 and raised its 1st funding round within a year of its incorporation.

Where is Immunome located?

Immunome is headquartered in Philadelphia, United States.

How many employees does Immunome have?

As of Mar 31, 2026, the latest employee count at Immunome is 222.

Is Immunome a funded company?

Immunome is a funded company, having raised a total of $54.2M across 19 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 10, 2008.

When was the latest funding round of Immunome?

Immunome's latest funding was a $***** Post IPO round on Apr 26, 2021, with participation from 0 investor.

What is the annual revenue of Immunome?

Annual revenue of Immunome is $6.94M as on Dec 31, 2025.

Where does Immunome rank among its competitors?

Immunome ranks 347th amongst 3177 active competitors, of which 1085 are funded.

Who are the top competitors of Immunome?

Immunome's top competitors include Jazz Pharmaceuticals, Moderna and Advanced Accelerator Applications. Among them, Immunome secured the most recent funding round in April, 2021.

Immunome - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of antibody-based therapeutics for treating cancer. Its lead oncology discovery program targets IL-38, a lesser-known member of the IL-1 family of cytokines. It allows tumors to evade the immune system response efforts. It utilizes B-cells from early-stage cancer patients and by using its fusion cell technology, RealMab, converts these B-cells into stable hybridomas that express thousands of affinity-matured monoclonal antibodies (mAbs) enriched for functional tumor antigen binding.

Website: immunome.com
Social
Email ID: *****@immunomeinc.com

Key Metrics

Founded Year

2008

Location

Philadelphia, United States

Stage

Public

Total Funding

$54.2M in 19 rounds

Latest Funding Round

Post IPO, Apr 26, 2021, $*****

Investors

Sea Purity Investments & 5 more

Ranked

347^th among 3177 active competitors

Annual Revenue

$6.94M as on Dec 31, 2025

Employee Count

222 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3039 more

Exit Details

Public

View Immunome's full profile

Immunome is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
IMMUNOME INC. CIN: 1472012 , United States, Active	Dec 01, 2015	$6.94M (As on Dec 31, 2025)	37 (As on Dec 31, 2022)	-
Immunome Inc. CIN: 77-0694340 , United States, Active		-	39 (As on Dec 31, 2021)	-

Immunome got listed on Oct 02, 2020.

Click here to take a look at Immunome's IPO in detail

Immunome has raised a total funding of $54.2M over 19 rounds. Its first funding round was on Jun 10, 2008. Immunome has 6 institutional investors.

Here is the list of recent funding rounds of Immunome:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 26, 2021	2842265	Post IPO	8672773	3229823	5460586	9408005
Jun 16, 2020	2590838	Series B	3261040	1546541	1266262	7599582
Nov 19, 2019	2426661	Series B	7859318	1084286	7025270	2017076

Access funding benchmarks and valuations. Sign up today!

View details of Immunome's funding rounds and investors

The founders of Immunome is Scott Dessain.

Here are the details of Immunome's key team members:

Scott Dessain: Founder & CTO of Immunome.
Jane Hollingsworth: ex-CEO of Immunome and founder of 1 other company.
Contact Info: 1 email address

View details of Immunome's Founder profiles and Board Members

Immunome's employee count trend

Immunome has 222 employees as of Mar 26. Here is Immunome's employee count trend over the years:

Uncover Immunome's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Immunome include Jazz Pharmaceuticals, Moderna and Advanced Accelerator Applications. Here is the list of Top 10 competitors of Immunome, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	81/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	HHS, Merck & 30 others	81/100
3rd	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Life Sciences Capital, Vivo Capital & 4 others	77/100
4th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, HealthCor Management & 15 others	75/100
5th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of drugs based on T-Cell receptor technology for the treatment of cancer	$601M	Malin PLC, General Atlantic & 50 others	75/100
6th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Zhongguancun Development Group ... & 13 others	74/100
7th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	PMV, VIB & 20 others	74/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 25 others	74/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Delos Capital Partners, RusnanoMedInvest ... & 19 others	74/100
10th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	74/100
347th	Immunome 2008, Philadelphia (United States), Public	Developer of antibody-based therapeutics for treating cancer	$54.2M	Sea Purity Investments, Evolution VC Partners ... & 4 others	60/100